---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-001953"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:10:38.919452+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Collegium Pharma guides FY2026 revenue $805-825M; Jornay PM $190-200M; adj. EBITDA $455-475M

## Summary
- Product revenue guidance $805-825M; Jornay PM net revenue $190-200M.
- Adjusted EBITDA guidance $455-475M, flat versus raised 2025 midpoint.
- Closed $980M syndicated credit facility; repaid $581M Pharmakon term loan, expects annualized interest savings.
- Signed supply/quality agreements with Hikma for authorized generics of Nucynta/Nucynta ER; AG Nucynta ER launch expected Q1 2026.

## SEC filing metadata
- accession: 0001104659-26-001953
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465926001953/0001104659-26-001953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465926001953/tm262493d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-001953
- JSON: https://secwatch.observer/filing/0001104659-26-001953.json
- Plain text: https://secwatch.observer/filing/0001104659-26-001953.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.